Live Breaking News & Updates on Axi Cel

Stay updated with breaking news from Axi cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Recent Data on Axi-Cel in Lymphoma

Dr Leslie discusses two abstracts on axi-cel recently presented at ASH 2023: a subgroup analysis of ZUMA-7 and the 4-year follow-up from ZUMA-5. ....

Lori Leslie , Jamesk Mccloskey , Gloria Leslie , Peer Exchange , Research Programs , John Theurer Cancer Center , Hackensack University Medical Center , Hackensack University Medical , Associate Professor , Indolent Lymphoma , Mash 2023 , Zuma 7 , Axi Cel , Largeb Cell Lymphoma , Older Population , Cart Cell Therapy , Car T , Overall Survival , Indolent Lymphomas , Follicular Lymphoma , Marginal Zone Lymphoma , Relapsed Refractory Follicular Lymphoma ,

Choosing CAR T-cells as Third-line and Beyond Therapy for FL

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL. ....

Jennifer Crombie , Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Beyond Therapy , Cart Cell Therapy , Head To Trial , Axi Cel , Tisa Cel , Grade 3 Crs , Liso Cel , Transcend Fl , Transcend Fl Trial ,

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma. ....

Gloria Leslie , Chronic Lymphocytic Leukemia Research Programs , Hackensack Meridian School Of Medicine , John Theurer Cancer Center , Indolent Lymphoma , Hackensack Meridian School , John Theurer Cancer Center , Axi Cel , Elderly Patients , Zuma 7 ,

CAR T-cells as Third-line and Beyond Therapy for FL

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL. ....

Bijal Shah , Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Beyond Therapy , Cart Cell Therapy , Zuma 5 , Axicabtagene Ciloleucel , Axi Cel , Tisa Cel , Pod 24 , Lisocabtagene Maraleucel , Liso Cel , Transcend Study , Elara Study ,

Axi-Cel Provides Sustained Response in High-Risk Large B-cell Lymphoma

Patients with high-risk large B-cell lymphoma experienced durable responses when treated with first-line axicabtagene ciloleucel, according to results from the phase 2 ZUMA-12 trial. ....

Julio Chavez , Lymphoma Section , Malignant Hematology , Moffitt Cancer Center , Axi Cel , Zuma 12 Trial , High Risk Largeb Cell Lymphoma , Ash Annual Meeting ,